Next-gen weight loss drugs will have fewer side effects than Ozempic, pharma CEO says
Zealand Pharma CEO Adam Steensberg said Friday that the company is working on a next-generation weight loss drug that’s designed to work differently from those currently on the market and with the potential for fewer side effects.
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
3don MSN
Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
Men, baby boomers, and postgraduate-degree holders were among those most likely to say they wouldn’t choose medication over ...
FDA halts actions on makers of compounded drugs as it reviews decision to remove Eli Lilly's (LLY) weight loss drug ...
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...
Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...
Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback